Literature DB >> 2826484

Molecular cloning of complementary DNA to mouse tissue plasminogen activator mRNA and its expression during F9 teratocarcinoma cell differentiation.

R J Rickles1, A L Darrow, S Strickland.   

Abstract

Two tissue plasminogen activator (tPA) cDNA clones were isolated from mouse cDNA libraries and characterized. The sequence coding for mature mouse tPA protein including its 29-residue signal peptide, as well as that for the 3' and part of the 5'-nontranslated regions of the mRNA was determined. The mature protein consists of 530 amino acids and is encoded by a transcript of approximately 2800 nucleotides. The mouse tPA protein has 81% homology with its human counterpart, and amino acid sequence conservations suggest that the multidomain-like structure found for human tPA is maintained in the mouse enzyme. The tPA cDNA has been used as a probe to analyze tPA gene expression during F9 cell differentiation. tPA mRNA is not detected in F9 stem cells. When F9 cells are induced to differentiate with retinoic acid and dibutyryl cyclic AMP, tPA mRNA accumulates. We demonstrate that this induction occurs at least in part because of an increase in tPA gene transcription.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826484

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

1.  Adenovirus infection of differentiated F9 cells results in a global shut-off of differentiation-induced gene expression.

Authors:  R J Weigel; J R Nevins
Journal:  Nucleic Acids Res       Date:  1990-10-25       Impact factor: 16.971

2.  Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo.

Authors:  P Burfeind; C L Chernicky; F Rininsland; J Ilan; J Ilan
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Adenovirus E1A-mediated negative control of genes activated during F9 differentiation.

Authors:  K S Young; R Weigel; S Hiebert; J R Nevins
Journal:  Mol Cell Biol       Date:  1989-07       Impact factor: 4.272

4.  Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator.

Authors:  T H Bugge; M J Flick; M J Danton; C C Daugherty; J Romer; K Dano; P Carmeliet; D Collen; J L Degen
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-11       Impact factor: 11.205

5.  Masking, unmasking, and regulated polyadenylation cooperate in the translational control of a dormant mRNA in mouse oocytes.

Authors:  A Stutz; B Conne; J Huarte; P Gubler; V Völkel; P Flandin; J D Vassalli
Journal:  Genes Dev       Date:  1998-08-15       Impact factor: 11.361

6.  Nervous system-specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury.

Authors:  I A Scarisbrick; M D Towner; P J Isackson
Journal:  J Neurosci       Date:  1997-11-01       Impact factor: 6.167

7.  Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hypoxia promotes pulmonary vascular fibrin deposition.

Authors:  D J Pinsky; H Liao; C A Lawson; S F Yan; J Chen; P Carmeliet; D J Loskutoff; D M Stern
Journal:  J Clin Invest       Date:  1998-09-01       Impact factor: 14.808

8.  The kidney is a major site of alpha(2)-antiplasmin production.

Authors:  P A Menoud; N Sappino; M Boudal-Khoshbeen; J D Vassalli; A P Sappino
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

9.  Expression levels of heat shock factors are not functionally coupled to the rate of expression of heat shock genes.

Authors:  M Victor; B J Benecke
Journal:  Mol Biol Rep       Date:  1998-07       Impact factor: 2.316

10.  Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator.

Authors:  K Yamamoto; D J Loskutoff
Journal:  J Clin Invest       Date:  1996-06-01       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.